This study, called MATIC-2, is for children under 18 who have severe bleeding from an injury (hemorrhagic shock) and might need a lot of blood. Researchers are comparing two different blood products: Low Titer Group O Whole Blood (LTOWB) and Component Therapy (CT), which is a mix of red blood cells, plasma, and platelets. They are also testing a medicine called Tranexamic Acid (TXA) against a placebo (an inactive substance). The main goal is to see if LTOWB or TXA can reduce the number of deaths within 24 hours after the injury. You might be able to join if you are a child under 18 with a traumatic injury and suspected life-threatening bleeding, especially if you have low blood pressure or a fast heart rate for your age. The study is currently unclear on its recruitment status and plans to enroll 1000 children.

Study design

This is a randomized, multicenter study where participants will be assigned by chance to receive either LTOWB or CT, and either Tranexamic Acid or a placebo. The study plans to enroll 1000 children.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, all-cause mortality, is measured at 24 hours.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.